Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27771655 | 0.95 | HRH3 (0.34) | HIF1AEPAS1HCAR2HCAR3 | |
| SCHEMBL16446651 | 0.87 | CYSLTR2 (0.33) | — | |
| SCHEMBL370841 | 0.74 | TDP1 (0.35) | HCAR2HCAR3MAPT | |
| SCHEMBL6261189 | 0.74 | HIF1A (0.40) | HIF1AEPAS1HCAR2HCAR3GPR84 | |
| SCHEMBL1228572 | 0.73 | HCAR2 (0.37) | HCAR2HCAR3GPR84 | |
| SCHEMBL20734522 | 0.73 | KCNH2 (0.37) | HCAR2GPR84MAPT | |
| SCHEMBL5815987 | 0.73 | DHFR (0.40) | HCAR2HCAR3GPR84MAPT | |
| SCHEMBL574839 | 0.73 | HCAR2 (0.40) | HIF1AHCAR2HCAR3MAPT | |
| SCHEMBL28300224 | 0.73 | LIPG (0.38) | HCAR2GPR84MAPT | |
| SCHEMBL28300226 | 0.73 | LIPG (0.38) | HCAR2GPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-8188080-B2 | VHR protein tyrosine phosphatase inhibitors, compositions and methods of use | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090105254-A1 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105254-A1 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | PTPRR, PTPRS, PTPRCAP | HIF1A 4231/4885EPAS1 2355/4885HCAR2 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.